WSGR logoWSGR logo

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

News Articles
John Lynch Honored Among The National Law Journal’s 2026 “Community Impact Leaders” Finalists
Bylined Articles
Law360 Article: “Drug Rulings Clarify Pricing Test and Penalty Reviews”
Bylined Articles
Blake Brief: The Space Operator's Guide to U.S. Spectrum Policy and the Direct-to-Device (D2D) Deal Market
Leading Matters
Client Highlights
Wilson Sonsini Advises Wafer on $40 Million Series A
On September 1, 2026, Wafer, an AI start-up developing a technology that continuously optimizes AI inference deployments, announced it has raised $40 million in a Series A financing round. The round was co-led by Marathon and Chemistry, with participation from Wing, AMD Ventures, and Outset Capital, as well as existing investors Fifty Years and Y Combinator. Wilson Sonsini Goodrich & Rosati advised Wafer on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Fambot on $3.5 Million Pre-Seed Funding
On September 1, 2026, Fambot, an AI "chief of staff" for families, launched and announced a $3.5 million pre-seed round, co-led by NextView Ventures and Baukunst. Correlation Ventures, Karman Ventures, and Founders Network also participated in the round. Wilson Sonsini Goodrich & Rosati advised Fambot on the transaction.
Learn More
Client Highlights
Firm Advises PMV Pharmaceuticals on Oversubscribed $50 Million Public Offering
On August 31, 2026, PMV Pharmaceuticals, a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced the pricing of an underwritten public offering consisting of 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, as well as accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The combined public offering price of each share of common stock and accompanying warrant is $1.21. The gross proceeds from the offering, before deducting underwriting discounts, commissions, offering expenses, and any exercise of the warrants, are expected to be approximately $50.8 million. Wilson Sonsini Goodrich & Rosati advised PMV Pharma on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Forte Biosciences on Completion of Acquisition by argenx
Wilson Sonsini is pleased to have represented Forte Biosciences in its recently completed acquisition by argenx.
Learn More
Client Highlights
Firm Advises Mara on $7 Million Funding Round
On August 26, 2026, Mara, a defense hardware start-up, announced a $7 million funding round to bring Spike, its integrated counter-UAS platform designed for the small, inexpensive FPV drones reshaping modern conflict, from field testing to broad combat deployment. The round was led by Khosla Ventures, with participation from a16z Speedrun, Night Capital, Palmdrive, Protagonist, Freedom Fund, and Indicator Fund, alongside angel investors. Wilson Sonsini Goodrich & Rosati advised Mara on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Altruist on Acquisition by Vanguard
On August 26, 2026, Vanguard and Altruist, an AI-forward wealth technology and custody platform serving financial advisors, announced that they have entered into a definitive agreement under which Vanguard will acquire Altruist. Wilson Sonsini Goodrich & Rosati is advising Altruist on the transaction.
Learn More
See More Leading Matters
The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.

Read More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.